Shots:

• The approval of Minnebro (Esaxerenone) tablets (1.25/2.5/5 mg) is based on P-III ESAX-HTN study in patients with hypertension- with its regulatory approval submitted to MHLW in Feb’18
• In Q2’19- Exelixis will receive $20M as milestone payment from Daiichi- as per their research collaboration for the development of therapies targeting mineralocorticoid receptor signed in 2006
• Minnebro (Esaxerenone) tablets are mineralocorticoid receptor blocker targeted to treat patients with hypertension- and is currently evaluated in P-III ESAX-DN study for patients with diabetic nephropathy by Daiichi in Japan

Ref: Exelixis | Image: Brand Navigation